Select Page

Department of Justice begins new crackdown on Pharma firms to combat opioid crisis – healthcare stocks in focus

by | 28 Feb, 2018

Jeff Sessions is spearheading a fresh approach to the opioid crisis

In a move that may put more pressure on pharmaceutical stocks, the Department of Justice in the U.S. is cracking down on the opioid crisis with a “Prescription Interdiction and Litigation Task Force” that will target drug manufacturers.

In reference to the actions the DoJ intends to take, Attorney General Jeff Sessions (pictured) said: “We will use criminal penalties, we will use civil penalties. We will use whatever laws and tools we have to hold people accountable.”

The DoJ is also backing up major lawsuits brought against companies including Johnson & Johnson, CVS, Cardinal Health, McKesson and Teva Pharmaceuticals by hundreds of cities, states and local governments. Investors with an interest in the healthcare sector should keep an eye on the share prices of these businesses in the weeks ahead! Several high profile drugmakers including Purdue Pharma already stopped promoting the drugs in light of the epidemic.

The move from the Trump administration is the latest major advancement in tackling America’s opioid health crisis. Back in January New York City sued 8 major pharmaceutical companies which manufacture prescription painkillers, with Mayor Bill de Blasio saying the lawsuit sought $500 million in damages to combat a problem which is responsible for more American deaths on an annual basis than homicides and car accidents combined.

The crisis became a public health emergency in October last year.

Want to learn more about the markets and how to become a better investor?

Download the Invstr App now.

All emails include an unsubscribe link. You can opt-out at any time. ​See our privacy policy.

ALL RIGHTS RESERVED © INVSTR LTD. 2018

Risk Disclosure:
Invstr is a technology platform, not a registered broker-dealer or investment adviser. Invstr does not offer its own recommendations of any security or provide its own research to any user regarding any security transaction or order.
Please note, investing involves risk and investments may lose value. Past performance does not guarantee future results.
Brokerage services are provided by the following:
US-traded securities, including fractional trading, are provided to Invstr users by DriveWealth LLC, a regulated member of FINRA/SIPC. DriveWealth may not establish investment accounts to residents of certain jurisdictions. For more information, including disclaimers, risk and transaction fees click here.
India account traded securities are provided by SIC Stocks & Services PVT Ltd. SIC does not make any personal recommendations to buy, sell or otherwise deal in investments. Investors make their own investment decisions. The services and securities provided by SIC may not be suitable for all customers and, if you have any doubts, you should seek advice from an independent financial adviser. For more information and disclaimers, click here.

Download on the App Store           Download on Google Play

ALL RIGHTS RESERVED © INVSTR LTD. 2018

Risk Disclosure:
Invstr is a technology platform, not a registered broker-dealer or investment adviser. Invstr does not offer its own recommendations of any security or provide its own research to any user regarding any security transaction or order.
Please note, investing involves risk and investments may lose value. Past performance does not guarantee future results.
Brokerage services are provided by the following:
US-traded securities, including fractional trading, are provided to Invstr users by DriveWealth LLC, a regulated member of FINRA/SIPC. DriveWealth may not establish investment accounts to residents of certain jurisdictions. For more information, including disclaimers, risk and transaction fees click here.
India account traded securities are provided by SIC Stocks & Services PVT Ltd. SIC does not make any personal recommendations to buy, sell or otherwise deal in investments. Investors make their own investment decisions. The services and securities provided by SIC may not be suitable for all customers and, if you have any doubts, you should seek advice from an independent financial adviser. For more information and disclaimers, click here.

 

Share This